Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The benefit-harm ratio of PSA screening can be dramatically improved by avoiding screening, biopsy and treatment in men who are unlikely to benefit, and by referring men that do need treatment to high volume centers.

Original publication

DOI

10.1016/j.eururo.2013.12.049

Type

Journal article

Journal

Eur Urol

Publication Date

08/2014

Volume

66

Pages

188 - 190

Keywords

Biopsy, Early Detection of Cancer, Hospitals, High-Volume, Humans, Informed Consent, Male, Prostate, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk Assessment